CRISPR Therapeutics (CRSP) Debt to Equity (2015 - 2026)
CRISPR Therapeutics (CRSP) debt to equity from Dec 31, 2015 to Mar 31, 2026. The current CRISPR Therapeutics (CRSP) debt to equity is 32.27%. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Debt to Equity
Annual Debt to Equity change of CRISPR Therapeutics (CRSP)
| Year | Debt to Equity | Change |
|---|---|---|
| 2026 | 32.27% | N/A |
| 2025 | 0.00% | N/A |
| 2024 | 0.00% | N/A |
| 2023 | 0.00% | N/A |
| 2022 | 0.00% | N/A |
| 2021 | 0.00% | N/A |
| 2020 | 0.00% | N/A |
| 2019 | 0.00% | N/A |
| 2018 | 0.00% | N/A |
| 2017 | 0.00% | N/A |
| 2016 | 0.00% | N/A |
| 2015 | 0.00% | N/A |
Comparison CRISPR Therapeutics (CRSP) debt to equity with competitors
CRISPR Therapeutics (CRSP) debt to equity is 32.27%.